Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

By D. V. Von Hoff, P. LoRusso, C. Rudin, J. Reddy, R. Yauch, R. Tibes, G. Weiss, M. Borad, C. Hann, J. Brahmer and 6 more. New England Journal of Medicine, 2009

1,112 citations recorded by the source corpus.

Subfields: Dermatology, Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b46ab53c66ea2e0f0597bacea1b4b19e2566457e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. C. Day
2. S. Bellentani
3. V. Ratziu
4. H. Cortez‐Pinto
5. Giulio Marchesini
6. D. Hanahan

In Molecular Biology

1. D. Hanahan

Citations in the corpus

• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “This results in a pro-fibrogenic myofibroblast-like cell population, controlled by the hedgehog pathway [155] and amenable to pharmacological modulation [156].”
• Hallmarks of Cancer: New Dimensions. (2022, background): “A third example also reveals transdifferentiation as a strategy employed by carcinoma cells to avoid elimination by a lineage-specific therapy, in this case involving basal cell carcinomas (BCC) of the skin treated with a pharmacologic inhibitor of the Hedgehog-Smoothened (HH/SMO) oncogenic signalin”
• Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways (2011, background): “The GDC-0449 study in 33 patients with advanced BCC reported two complete responses and 16 partial responses”